PureTech Presents Phase 2b Open-Label Extension Data Showing Deupirfenidone Stabilizes Lung Function In IPF With Favorable Tolerability

Patients who switched from placebo or pirfenidone to deupirfenidone in the open-label extension study achieved stabilization of lung function with favorable tolerability

Findings further substantiate safety and efficacy results from the randomized, placebo- and active-controlled 26-week trial and highlight opportunity to address patients inadequately served by current therapies

Regulatory engagement underway; update on Phase 3 trial design expected in Q4 2025